Zynrelef Heron Therapeutics, B.V. · Withdrawn · authorised 24 Sep 2020 · ATC N01B
Therapeutic indication (EMA)
Zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.1).
Active substances
Bupivacaine + Meloxicam
- US FDA 2
- EMA 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZYNRELEF KIT | 200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML); 400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | solution, extended release · periarticular | HERON THERAPS INC | Prescription | 12 May 2021 |
| ZYNRELEF KIT | 60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML); 300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | solution, extended release · periarticular | HERON THERAPS INC | Discontinued | 12 May 2021 |
EMA European Union — centrally authorised medicines
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.